Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2025 07:00 ET | Source: Treos Bio Corp.

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

LONDON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- TREOS Bio Ltd., a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, today announced the...
August 11, 2025 09:00 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™.

Delray Beach, FL, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The global cancer vaccines market is on track to nearly double over the next decade, climbing from USD 9.84 billion in 2024 to USD 15.00 billion...
January 14, 2025 07:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Cancer Vaccines Market to Hit US$ 20.47 Billion by 2032 with 8.6% CAGR | MarketsandMarkets™.

Delray Beach, FL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The global cancer vaccines market, valued at US$10.23 billion in 2023, is forecasted to grow at a robust CAGR of 8.6%, reaching US$10.61 billion...
September 09, 2024 16:16 ET | Source: Treos Bio Corp.

New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes

LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
August 14, 2024 07:00 ET | Source: Achilles Therapeutics PLC

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa...
July 30, 2024 06:45 ET | Source: BioNTech SE

BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt

Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
July 30, 2024 06:45 ET | Source: BioNTech SE

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
June 03, 2024 07:00 ET | Source: Treos Bio Corp.

At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer

Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
May 22, 2024 07:00 ET | Source: Achilles Therapeutics PLC

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
May 08, 2024 07:45 ET | Source: Treos Bio Corp.

Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting

LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...